Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Blood plasma toxins and inflammatory mediators refer to a broad spectrum of pathogenic molecules that accumulate in the systemic circulation during acute and chronic disease states. This category encompasses pathogen-associated molecular patterns (PAMPs) like endotoxins, damage-associated molecular patterns (DAMPs), and a wide array of pro-inflammatory cytokines such as IL-1β, IL-6, and TNF-α [1][3]. These mediators are pivotal in driving the dysregulated host response seen in sepsis, cytokine release syndrome (CRS), and multi-organ dysfunction syndrome (MODS) [2]. From a therapeutic perspective, these substances are targeted either through specific pharmacological inhibition using monoclonal antibodies or through broad-spectrum extracorporeal removal techniques like hemoperfusion and high-cutoff hemodialysis [4][6]. The primary challenge in targeting this group lies in the double-edged sword nature of the immune response, where excessive removal may impair necessary host defense mechanisms or inadvertently clear essential medications [5]. Managing the levels of these toxins is crucial for stabilizing critically ill patients and preventing the progression of inflammatory cascades [6]. Sources: [1] Chousterman BG, et al. (2017). Cytokine Storm and Sepsis Disease Pathogenesis. Seminars in Immunopathology. [2] Singer M, et al. (2016). The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. [3] Ronco C, et al. (2017). Extracorporeal Blood Purification and Organ Support in the Critically Ill Patient. Nature Reviews Nephrology. [4] Monard C, et al. (2023). Extracorporeal Cytokine Adsorption in Septic Shock. Critical Care. [5] Vanholder R, et al. (2003). Review on uremic toxins: Classification, concentration, and interindividual variability. Kidney International. [6] Rimmelé T, et al. (2023). Extracorporeal Blood Purification Therapy for Sepsis. Blood Purification.
Extracorporeal adsorption, filtration, or pharmacological neutralization of circulating pathogenic molecules to mitigate systemic inflammation and prevent organ damage [3][4].
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Blood plasma toxins and inflammatory mediators.